Reinsurance Group of America, Incorporated · NYSE:RGA

Reinsurance Group of America — Best Practices on Genetic Testing – The way forward, Session 1 (HKFI) (October 2020)

26 slides from Reinsurance Group of America's conference presentation, Oct 27, 2020

  1. Slide 1: Best Practices on Genetic Testing – The way forward

    Best Practices on Genetic Testing – The way forward Session 1: Get ready for a genetic moratorium (era) Presenter: Moderator: • Dr. Heather Lund • Dipali Jawalkar • Dr. Summer Zhu 27.10.2020 1

  2. Slide 2: Agenda

    Agenda 01 Genomics and genetic testing 02 HKFI Best Practices & Principles 03 What now and what next 04 Q & A Best Practices on Genetic Testing – The way forward – session 1 2

  3. Slide 3: Genomics and genetic testing

    Genomics and genetic testing 3

  4. Slide 4: Genomics

    Genomics ~ 2 meters Single nucleotide polymorphisms (SNPs) = variations of a base pair, in 10^7 Letter by letter = sequence 3 x 10^9 (billions)  = Exome =2% Genome GWAS, SNP chips ~20,500 D N Genome X23 pairs Disease TBD Associated Imaging/sorting chromosomes ~4000 Alleles = versions (sequence = Ka

  5. Slide 5: Validity of Genetic Testing

    Validity of Genetic Testing  Analytic validity: a test’s accuracy in detecting a particular genetic variant when present and not detecting the variant when absent  Clinical validity: What is the ability of a test to distinguish whether someone has, will, or will not develop a condition. – Correlat

  6. Slide 6: Clinical Genetic Testing: Who, What and When?

    Clinical Genetic Testing: Who, What and When? To confirm a clinical diagnosis or identify possible genetic cause of a condition Begin genetic testing in a Will depend on what is Younger age of onset and clearly affected person = index found +ve family history increase case or proband the pretest pro

  7. Slide 7: Clinical Genetic Testing: Results

    Clinical Genetic Testing: Results Standardization across laboratories Genetic testing report results section Interpretation section  List of variants identified  Supporting data for variant classification  Gene name  Predicted effect of the genetic  Nomenclature at: variant on the protein – the

  8. Slide 8: Genes are Not Fate

    US$ 199 Genes are Not Fate: • • BRCA1/BRCA2 Parkinson's disease, • Late-onset Alzheimer's disease,  Direct to Consumer (DTC) Genetic Testing • • Celiac disease, Alpha-1 antitrypsin deficiency, • Early-onset primary dystonia, – Not just ancestry and paternity • Factor XI deficiency, – Most are genot

  9. Slide 9: HKFI Best practices and principles

    HKFI Best practices and principles 9

  10. Slide 10: How did we arrive at the six conditions for HKFI?

    How did we arrived at the six conditions for HKFI?  Reliable testing is clinically available & widely recognized by clinical guidelines  Robust medical science and statistical evidence to confirm associated risk- class difference for products sold in HK – Monogenic – Autosomal dominant inheritance

  11. Slide 11: Six Conditions

    Six Conditions Hereditary Breast and Ovarian Huntington’ Disease Cancer Syndrome Autosomal Dominant Early–onset Autosomal Polycystic Kidney Disease Dominant Alzheimer Disease (ADPKD) (EAOD) Lynch Syndrome/Hereditary Hypertrophic Cardiomyopathy Non-polyposis Colorectal (HOCM) Cancer Best Practices on

  12. Slide 12: For example: Polycystic kidney disease (PKD)

    For example: Polycystic kidney disease (PKD)  Autosomal dominant polycystic kidney disease (ADPKD) has a prevalence of 1:500 – 2500 Hypertension Brain aneurysm  Accounting for about 10% of end-stage renal disease Liver cyst Aorta and coronary  Two main* causative genes, PKD1 and PKD2 Pancreas cys

  13. Slide 13: Best practices: What now and what next?

    Best practices: What now and what next? 13

  14. Slide 14: Current and future state

    Current and future state Genetic reference in cases seen at RGA Family history Renal cysts Neurology Polycystic kidney disease Endocrine Cystic fibrosis Breast Cancer Huntington's Cancer - Other Alzheimer's Benign tumors Lynch Syndrome Heart disorders Others 2015 2016 2017 2018 2019 2020 Best Practi

  15. Slide 15: Real cases can be complicated

    Real cases can be complicated  A 35-year-old male: – Employer-provided health check-up recorded BP 140/90 mmHg; – Renal USG showed 3 renal cysts on the Lt, and 1 one the right; – MSU and KFT were within normal range; – His father passed away at age 48; – He and his wife plan to start a family. For

  16. Slide 16: There are a lot to think about before the genetic test

    There are a lot to think about before the genetic test • Was there any other findings from the health check-up? • Any past imaging for comparison? • Can we get clarification on the f/hx, any other family member affected? • Has he consulted a doctor about his BP, renal USG findings and family history

  17. Slide 17: 'Predictive' vs 'Diagnostic'

    ‘Predictive’ vs ‘Diagnostic’ (a) Diagnostic genetic testing Diagnostic or confirmatory genetic testing is to identify or confirm a specific genetic or chromosomal condition in a symptomatic individual. Predictive (b) Diagnostic (b) Predictive genetic testing Predictive and pre-symptomatic genetic te

  18. Slide 18: Real cases can be complicated

    Real cases can be complicated  A 3 months old boy: – First trimester screening: high risk oNuchal translucency (NT) >95th% – Genetic amniocentesis: oFetal karyotype (chromosome exam) normal oFetal DNA found duplication of 3p26.3 of ~436kb involving exons of CNTN6 gene. – Inherited from clinically w

  19. Slide 19: A gentle reminder

    A gentle reminder  Get familiar with relevant genetic terms (GULF and others);  Fully grasp best practice principles, particularly the definition of genetic testing, diagnostic/predictive;  Provide the opportunity to the applicant to provide detailed medical and family history information, includ

  20. Slide 20: Genetics: RGA at the forefront

    Genetics: RGA at the forefront 20

  21. Slide 21: RGA leads in the adaptation of life insurance into this new era

    RGA leads in the adaptation of life insurance into this new era  RGA Research Collaboration with King’s College London Maxwell JM, Russel R et. al. Multifactorial disorders and polygenic risk scores: predicting common diseases and Best Practices on Genetic Testing – The way forward – session 1 the

  22. Slide 22: RGA leads in the adaptation of life insurance into this new era

    RGA leads in the adaptation of life insurance into this new era  Representation on: – ABI Genetics Working Group – American Council of Life Insurers (ACLI) – HKFI – SG LIA – NZ FSC  White Paper: Genetics and Insurance  COVID-19 Brief: COVID and Genetics  Ensure global underwriting manual (GUM) d

  23. Slide 23: Q&A

    Q&A 23

  24. Slide 24: Way forward

    Way forward  New space, evolving information and layer of regulation – requires collaboration and patience  Element of exclusivity - might warrant different handling  Monitoring and analysis by industry - contribute towards insights and evidence alongside healthcare and research institutions  Di

  25. Slide 25: ©2019 RGA. All rights reserved.

    ©2019 RGA. All rights reserved. No part of this publication may be reproduced in any form without the prior permission of RGA. The information in this publication is for the exclusive, internal use of the recipient and may not be relied upon by any other party other than the recipient and its affili

  26. Slide 26: Best Practices on Genetic Testing – The way forward

    Best Practices on Genetic Testing – The way forward Session 1: Get ready for a genetic moratorium (era) Presenter: Moderator: • Dr. Heather Lund • Dipali Jawalkar • Dr. Summer Zhu 27.10.2020 26

Reinsurance Group of America — Best Practices on Genetic Testing – The way forward, Session 1 (HKFI) (October 2020) on 6ix